Apos® Recognised by NICE and NHS England's MedTech Funding Mandate

Apos® has been recognised in two important NHS milestones: it is recommended in NICE guidance HTG671 for people with knee osteoarthritis, and it has been selected for NHS England’s MedTech Funding Mandate. Together, these announcements support wider access to a non-invasive option for people living with persistent knee pain.

The NICE recommendation gives NHS teams clear guidance on the role of Apos® for knee osteoarthritis. The MedTech Funding Mandate identifies Apos® as a cost-saving solution, helping health services consider treatment that can support patients while making thoughtful use of NHS resources.

For patients and families, recognition through the NHS gives Apos® a clearer place in the conversation about what to try when knee osteoarthritis starts to limit everyday life. It also gives health professionals a practical, evidence-led option to discuss alongside the other forms of support available for people who want to remain active.

For patients, the significance is practical. Apos® can help support movement and day-to-day function, which may help some people avoid or delay surgery. That matters as the NHS continues its work to reduce waiting lists and support elective recovery, while giving people another route to explore for ongoing knee osteoarthritis.

Apos® is now available within the NHS alongside private and insurance routes. This means access can be considered through the pathway that fits a person’s circumstances, whether that is an NHS service, private care or an insurer-supported route. It is a meaningful step towards making evidence-led, non-invasive support more accessible to people who want to keep moving.